NACDS Web site refocuses on Marketplace Conference
ALEXANDRIA, Va. In preparation for the National Association of Chain Drug Stores Marketplace Conference, to be held June 5 to 8, 2010, in San Diego, NACDS said it has unveiled newly-developed Web site features with participants’ productivity in mind.
“NACDS is dedicated to providing innovative tools and resources to our member companies and conference attendees to ensure they have the most successful and productive conference experience,” said NACDS president and CEO Steve Anderson. “Redesigning and re-focusing our Marketplace Conference Web site is no exception. The new Eeb site provides tools that will enhance the efficiency and time-management of meeting attendees. The early projections for Marketplace are exciting, and that is a testament to NACDS’ ability to produce a value-driven meeting experience for suppliers and retailers.”
The new features are designed to provide conference attendees with more information on featured retailers, sales-boosting products and connect exhibitors and purchasers. Specifically, the enhanced site includes an updated floor plan with a more user-friendly look and feel, easier navigation tools, improved search capabilities, enhanced user-functionality and the ability to view assigned and unassigned exhibition booths.
Perrigo to manufacture Analpram HC for Ferndale Labs
ALLEGAN, Mich, Ferndale Labs has named generic drug maker Perrigo as the manufacturer of an authorized generic version of a topical skin cream, Perrigo announced Thursday.
The drug, Analpram HC, is a topical anesthetic and corticosteroid for relieving inflammatory and pruritic forms of corticosteroid-responsive dermatosis. Under the deal, Perrigo will also have the opportunity to distribute authorized generics of other Ferndale drugs.
“We are excited that Ferndale has chosen Perrigo as their preferred partner for authorized generics,” Perrigo chairman and CEO Joseph Papa said.
Par wins Zegerid patent suit
WOODCLIFF LAKE, N.J. The U.S. District Court for the District of Delaware has ruled in favor of generic drug maker Par Pharmaceutical in a patent litigation suit over a drug used to treat acid reflux, Par announced Thursday.
The court ruled that the University of Missouri’s patents covering omeprazole and sodium bicarbonate capsules in the 20-mg/1.1-g and 40-mg/1.1-g strengths and oral suspension powders in the 20-mg/1.68-g and 4- mg/1.68-g strengths are invalid. The Food and Drug Administration recently was granted tentative approval for both strengths of the capsule version.
Omeprazole and sodium bicarbonate is a generic version of Santarus’s drug Zegerid. Patents for the capsules and oral suspension powder are set to expire in 2016, according to FDA records. According to Santarus financial data, Zegerid capsules and oral suspension powder had combined sales of $119.3 million in 2009.
Santarus said Wednesday that it would appeal the District Court’s decision to the U.S. Court of Appeals for the Federal Circuit.